LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study is a research paper published in Annals of Oncology (2022). On theSindex it has a DataRank of 2.7. It has been cited 39 times, with 37 citing works in its 1-hop citation network.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.553
From this paper's citation signal
Citation Network Contribution
2.2
From 33 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 37 citers.
FWCI
5.34
Citation Percentile
1.0%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals